EUVIMEDEUVIMED entdecken
Crossref

Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC

Mohamed K Elgohary iD, Mahmoud S Elkotamy, Zainab M Elsayed, Abrar Mortada Abdelraheem, Ibrahim Taha Radwan, Eman Darweish iD, Abdulrahman A Almehizia iD, Ahmed M Naglah iD, Fahad A Almehizia, Mohamed Fares, Wagdy M Eldehna iD, Hatem A Abdel-Aziz

Drug Development Research · 2026-02 · 87 (1)

DOI: 10.1002/ddr.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 17.12.2025. Verfasst von Mohamed K Elgohary und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt. Hauptthemen laut MEDLINE: Lung Neoplasms, Triazoles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: King Saud University, Egyptian Russian University, Kafrelsheikh University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of triazole hydrazide derivatives 8a‐o was rationally designed, synthesized, and systematically evaluated for their anticancer potential. Cytotoxicity screening against A549 lung adenocarcinoma cells identified compounds 8a‐d as the most potent, exhibiting IC 50 values of 3.15–4.93 µM, which are comparable to doxorubicin (IC 50 = 2.77 µM). Mechanistic studies revealed that lead compound 8a induced apoptosis through upregulation of Bax and caspase‐3 and downregulation of Bcl‐2. Additionally, 8a significantly inhibited A549 cell migration (34.46% wound closure vs. 61.61% in controls) and reduced clonogenic survival (surviving fraction = 0.5725). Importantly, 8a displayed low cytotoxicity toward normal lung fibroblasts (WI‐38, IC 50 = 47.21 µM). Enzyme inhibition assays demonstrated potent EGFR kinase inhibition by 8a and 8 d (IC 50 = 74.85 and 75.87 nM, respectively), comparable to erlotinib (IC 50 = 34.89 nM). Moreover, in silico ADMET profiling predicted favorable drug‐likeness and oral bioavailability, while molecular docking supported the stable binding of 8a within the EGFR active site. These findings identify compound 8a as a promising therapeutic lead for the development of targeted EGFR inhibitors in non‐small cell lung cancer (NSCLC) therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsTriazolesAntineoplastic AgentsCarcinoma, Non-Small-Cell LungProtein Kinase InhibitorsThiazolesHumansErbB ReceptorsMolecular Docking SimulationDrug DesignApoptosisA549 CellsCell Line, TumorStructure-Activity RelationshipCell Movement

Stichwörter der Autor:innen

EGFR inhibitionNSCLCmechanistic studies wound healing

Substanzen

ErbB ReceptorsTriazolesAntineoplastic AgentsEGFR protein, humanProtein Kinase InhibitorsThiazoles

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alsalam University, Kafr El Zayat, Egypt.
  • Scientific Research and Innovation Support Unit, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
  • Supplementary General Sciences Department, Faculty of Oral and Dental Medicine, Future University in Egypt, Cairo, Egypt.
  • Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt.
  • Drug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Mohamed K Elgohary, Eman Darweish, Abdulrahman A Almehizia, Ahmed M Naglah, Wagdy M Eldehna

Förderung

  • King Saud University
  • Egyptian Russian University
  • Kafrelsheikh University
  • University of Sydney
  • National Research Center

Zitieren

APA

Elgohary, M. K., Elkotamy, M. S., Elsayed, Z. M., Abdelraheem, A. M., Radwan, I. T., Darweish, E., Almehizia, A. A., Naglah, A. M., Almehizia, F. A., Fares, M., Eldehna, W. M., & Abdel-Aziz, H. A. (2026). Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC. Drug Development Research, 87(1). https://doi.org/10.1002/ddr.70211

Vancouver

Elgohary MK, Elkotamy MS, Elsayed ZM, Abdelraheem AM, Radwan IT, Darweish E, et al. Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC. Drug Development Research. 2026;87(1). doi:10.1002/ddr.70211

BibTeX
@article{Elgohary2026,
  author = {Elgohary, Mohamed K and Elkotamy, Mahmoud S and Elsayed, Zainab M and Abdelraheem, Abrar Mortada and Radwan, Ibrahim Taha and Darweish, Eman and Almehizia, Abdulrahman A and Naglah, Ahmed M and Almehizia, Fahad A and Fares, Mohamed and Eldehna, Wagdy M and Abdel-Aziz, Hatem A},
  title = {Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {1},
  doi = {10.1002/ddr.70211}
}
Kostenlos starten →